4D Molecular Therapeutics Announces Collaboration on Leading Machine Learning Technology and Expertise from U.C. Berkeley to Expand Therapeutic Vector Evolution Platform
04 mai 2021 16h02 HE
|
4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene...
4D Molecular Therapeutics to Participate in BofA Securities 2021 Virtual Health Care Conference
30 avr. 2021 07h05 HE
|
4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., April 30, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene...
4D Molecular Therapeutics Announces Preclinical Data Presentations at ASGCT and ATS Annual Meetings on Three Wholly-Owned Product Candidates from Non-Human Primate Studies
27 avr. 2021 16h31 HE
|
4D Molecular Therapeutics, Inc.
- Abstracts on 4D-150 for wet AMD/DME and 4D-310 for Fabry disease accepted for oral presentations at ASGCT 24th Annual Meeting - Abstract on 4D-710 for cystic fibrosis lung disease accepted for oral...
4D Molecular Therapeutics Reports Financial Results for the Year Ended December 31, 2020 and Provides Operational Highlights
25 mars 2021 16h02 HE
|
4D Molecular Therapeutics, Inc.
- First patient dosed in the 4D-310 Phase 1/2 clinical trial in Fabry disease - Intravitreal product candidates, 4D-125 for the treatment of XLRP and 4D-110 for the treatment of choroideremia,...
4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of 4D-310 for the Treatment of Fabry Disease
09 mars 2021 08h03 HE
|
4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: 4DMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene...
4D Molecular Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
15 déc. 2020 16h05 HE
|
4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., Dec. 15, 2020 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (4DMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene...
4D Molecular Therapeutics Announces Upsized Pricing of Initial Public Offering
10 déc. 2020 22h36 HE
|
4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., Dec. 10, 2020 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (4DMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene...